AMLX: Amylyx Pharmaceuticals, Inc. Total Debt to Capital

Amylyx Pharmaceuticals (AMLX) is betting on rare pathologies and the acquisition of avexitide to drive growth. The GURU.Markets website provides the debt-to-equity ratio trend, where 0.02 represents the current metric. However, risks are increasing due to the departure of some R&D specialists and a dependence on global component supply chains, which could hinder the international certification of drugs.

The price action of Amylyx Pharmaceuticals (AMLX) on this chart reflects the financing strategy for expansion within the neurodegenerative disease sector. The debt-to-equity ratio measures the extent of the business's reliance on external borrowings. This calculation is based on dividing total debt by the amount of shareholder equity. High leverage during the scaling of clinical trials may amplify volatility risks. It is critical for investors to monitor this balance to assess the long-term sustainability of the assets.